SCHEMBL3401965

SCHEMBL3401965

N[C@@H](CCC(=O)O)C(=O)OC(=O)[C@@H](N)Cc1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
MAPT P10636 2/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
MPO P05164 1/20 0.64
TSHR P16473 1/20 0.64
BLM P54132 1/20 0.64
PMP22 Q01453 1/20 0.64
KMT2A Q03164 1/20 0.64
HIF1A Q16665 1/20 0.64
TACR1 P25103 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.52
APAF1 O14727 1/20 0.51
POLB P06746 1/20 0.51
RECQL P46063 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HTR2A P28223 2/20 0.49
ADRB1 P08588 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6146846 0.91 MAPT (0.61) KDM4EMAPTMEN1LMNAMPO
SCHEMBL475351 0.90 MAPT (0.74) KDM4EMAPTMEN1LMNAMPO
SCHEMBL289044 0.90 MAPT (0.74) KDM4EMAPTMEN1LMNAMPO
SCHEMBL27522280 0.88 MAPT (0.64) KDM4EMAPTMEN1LMNAMPO
Dl-Tryptophan SCHEMBL8059982 0.86 KDM4E (0.82) KDM4EMAPTMEN1LMNAMPO
SCHEMBL31436164 0.86 KDM4E (0.69) KDM4EMAPTMEN1LMNAMPO
SCHEMBL120931 0.86 KDM4E (0.69) KDM4EMAPTMEN1LMNAMPO
Dl-Tryptophan SCHEMBL27153460 0.86 KDM4E (0.82) KDM4EMAPTMEN1LMNAMPO
Tryptophan SCHEMBL6688035 0.86 KDM4E (0.82) KDM4EMAPTMEN1LMNAMPO
SCHEMBL1132857 0.86 KDM4E (0.69) KDM4EMAPTMEN1LMNAMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604264-B1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES OBSHESTVO S OGRANICHENNOJ OTVETSTVENNOSTJU CYTONIR (RU) 2014-09-24 EP claimed
EP-2604264-A1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) 2013-06-19 EP claimed
CN-119968127-A Animal food compositions with improved palatability and customizable properties and methods of making the same 玛氏公司 2025-05-09 CN disclosed
CN-114269951-A Diagnostic method for aesthetic deterioration of skin 欧莱雅 2022-04-01 CN disclosed
EP-2601963-B1 N-ISOVALEROYL-L-GLUTAMYL-L-TRYPTOPHAN AS AN AGENT INHIBITING THE FORMATION OF ULCERS IN THE STOMACH AND THE DUODENUM OBSHESTVO S OGRANICHENNOJ OTVETSTVENNOSTJU CYTONIR (RU) 2015-04-22 EP disclosed
EP-2604264-B1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES OBSHESTVO S OGRANICHENNOJ OTVETSTVENNOSTJU CYTONIR (RU) 2014-09-24 EP disclosed
EP-2604264-A1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) 2013-06-19 EP disclosed
EP-2604264-A1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) 2013-06-19 EP disclosed
EP-2601963-A1 N-ISOVALEROYL-L-GLUTAMYL-L-TRYPTOPHAN AS AN AGENT INHIBITING THE FORMATION OF ULCERS IN THE STOMACH AND THE DUODENUM Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) 2013-06-12 EP disclosed
WO-2012087181-A1 PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ЦИТОНИР" (RU) 2012-06-28 WO disclosed
EP-2225386-A2 PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND Unilever PLC (GB) 2010-09-08 EP disclosed
WO-2009083454-A2 PROCESS FOR THE ENZYMATIC PREPARATION OF A GAMMA-GLUTAMYL COMPOUND UNILEVER PLC (GB) 2009-07-09 WO disclosed
US-20090169704-A1 Process for the enzymatic preparation of a gamma-glutamyl compound CONOPCO, INC. D/B/A UNILEVER 2009-07-02 US disclosed